Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in ...

New review confirms psychiatric safety of commonly used glucagon-like peptide 1 receptor agonists among patients without ...

A recent clinical trial published in the Journal of American Medical Association revealed that among individuals who are ...

Treating nicotine addiction with glucagon-like peptide 1 receptor agonists is associated with less weight gain compared with ...

Glucagon-like peptide 1 receptor agonist treatment is not associated with an increased risk for psychiatric adverse events or worsening depressive symptoms.

Research on weight loss drugs like Ozempic shows varied results for mental health impacts, with some patients experiencing ...

The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their ...

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.

GLP-1 RAs were associated with significant reductions in body weight, BMI, and waist circumference among pediatric patients with obesity.

Patients with diabetes mellitus who use GLP-1 RAs have an increased risk for acute and chronic pancreatitis, according to a study presented at DDW 2025.

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Risks for prostate cancer metastasis or death appeared lower with GLP-1 RA use compared with use of other antidiabetic drugs. Patients with prostate cancer who take glucagon-like peptide-1 ...